The global genomics data analysis market is projected to grow from $6.85 billion in 2024 to $28.74 billion by 2034, driven by advancements in sequencing technologies, personalized medicine demand, and AI-driven analytics.
Pacific Biosciences of California, Inc. (PACB)
Common Stock · Currency in USD · XNAS
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
Company Info
SIC3826
Composite FIGIBBG000QKXH20
CIK0001299130
IPOOct 27, 2010
Sectorlaboratory analytical instruments
Highlights
Market Cap$404.68M
EPS-$0.52
P/E Ratio-2.66
Revenue$156.41M
Gross Profit$63.60M
Net Income-$152.00M
Employees485
WSO301,998,292
Phone650-521-8000
Websitehttps://www.pacb.com
Related Tickers
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Pacific Biosciences of California, Inc., comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
Pacific Biosciences of California, Inc. (PACB) has returned -31.28% so far this year and 16.52% over the past 12 months. Looking at the last ten years, PACB has achieved an annualized return of -17.70%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
PACB
1M-7.90%
6M-11.26%
YTD-31.28%
1Y16.52%
5Y-46.88%
10Y-17.70%
Benchmark (SPY)
1M-2.61%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Pacific Biosciences of California, Inc. (PACB) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 15.90% | -25.33% | -18.01% | -1.47% | ||||||||
| 2025 | -16.76% | -3.33% | -19.73% | -9.02% | -13.96% | 26.53% | 10.40% | -4.38% | -1.54% | 85.71% | -0.85% | -16.22% |
| 2024 | -32.82% | -16.34% | -31.82% | -56.92% | 7.83% | -27.13% | 51.47% | -33.50% | 25.00% | 29.17% | -13.57% | -4.19% |
| 2023 | 33.37% | -18.78% | 27.25% | -8.38% | 17.01% | 8.04% | -0.38% | -13.76% | -27.58% | -25.09% | 35.25% | 16.51% |
| 2022 | -45.46% | 5.21% | -22.68% | -31.75% | -10.49% | -22.05% | -2.24% | 35.02% | 1.31% | 43.05% | 23.71% | -23.77% |
| 2021 | 24.20% | -7.99% | 2.78% | -13.40% | -8.31% | 28.10% | -8.14% | -2.97% | -18.37% | 3.80% | -12.55% | -12.45% |
| 2020 | -9.67% | -27.35% | -9.73% | 10.54% | 8.98% | -2.82% | 8.75% | 75.53% | 49.32% | 30.97% | 20.19% | 59.63% |
| 2019 | -6.23% | 5.79% | -1.23% | 1.93% | -9.46% | -10.10% | -11.62% | 2.59% | -6.69% | -5.84% | 6.20% | 0.39% |
| 2018 | 6.37% | -16.20% | -13.50% | 24.64% | -1.94% | 38.67% | 7.04% | 31.32% | 8.20% | -17.74% | 73.78% | -5.37% |
| 2017 | 26.18% | 3.91% | 1.17% | -23.94% | -16.88% | 5.95% | -8.68% | 51.84% | 5.63% | -19.89% | -25.29% | -16.98% |
| 2016 | 14.74% | 1.15% | -27.85% | 22.14% | -3.14% | 7.31% | -4.71% | -11.20% | -50.07% |
Performance Indicators
The charts below present risk-adjusted performance metrics for Pacific Biosciences of California, Inc. (PACB) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of PACB compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Pacific Biosciences of California, Inc. volatility is 3.90%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 784.08M | 1.26B | 1.75B | 1.77B | 2.01B | 413.98M | 147.99M | 170.28M | 144.08M | 137.88M | 131.11M | 124.52M | 136.19M | 129.68M | 218.32M |
| Equity Attributable To Parent (USD) | 5.35M | 506.59M | 701.30M | 562.90M | 790.99M | 335.49M | 54.92M | 114.06M | 86.10M | 84.67M | 73.54M | 54.95M | 69.18M | 109.38M | 191.46M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Equity (USD) | 5.35M | 506.59M | 701.30M | 562.90M | 790.99M | 335.49M | 54.92M | 114.06M | 86.10M | 84.67M | 73.54M | 54.95M | 69.18M | 109.38M | 191.46M |
| Other Non-current Liabilities (USD) | - | - | - | 44.16M | 248.21M | - | 28.04M | 14.67M | 15.71M | 3.34M | - | 23.96M | 31.10M | - | - |
| Long-term Debt (USD) | - | - | - | 896.68M | 896.07M | - | 15.87M | 14.66M | 13.64M | 16.11M | - | 14.12M | 13.35M | - | - |
| Noncurrent Liabilities (USD) | 705.90M | 687.55M | 949.68M | 940.85M | 1.14B | 39.99M | 43.92M | 29.33M | 29.35M | 19.44M | 19.39M | 38.09M | 44.45M | 5.56M | 7.48M |
| Other Current Liabilities (USD) | 33.81M | 38.00M | 50.63M | 233.88M | 35.43M | 19.66M | 31.04M | 11.63M | 11.97M | 16.85M | 25.30M | 19.56M | 15.69M | 7.10M | 14.63M |
| Wages (USD) | 18.25M | 11.71M | 29.34M | 17.43M | 25.28M | 15.26M | 9.75M | 8.52M | 7.57M | 8.56M | 8.13M | 6.33M | 5.15M | 4.66M | - |
| Accounts Payable (USD) | 20.77M | 16.59M | 15.06M | 12.03M | 11.00M | 3.58M | 8.37M | 6.74M | 9.09M | 8.36M | 4.75M | 5.61M | 1.72M | 2.99M | 4.74M |
| Current Liabilities (USD) | 72.83M | 66.30M | 95.03M | 263.34M | 71.71M | 38.50M | 49.15M | 26.88M | 28.64M | 33.77M | 38.18M | 31.49M | 22.56M | 14.74M | 19.38M |
| Liabilities (USD) | 778.73M | 753.85M | 1.04B | 1.20B | 1.22B | 78.49M | 93.07M | 56.21M | 57.98M | 53.22M | 57.57M | 69.57M | 67.01M | 20.30M | 26.85M |
| Other Non-current Assets (USD) | 369.76M | 344.69M | 510.55M | 463.19M | 462.35M | 33.49M | 36.87M | 4.54M | 4.55M | 14.31M | 12.02M | 162.00K | 490.00K | 354.00K | 317.00K |
| Intangible Assets (USD) | 15.12M | 389.57M | 456.98M | 410.25M | 410.98M | - | - | - | - | - | - | - | - | - | - |
| Fixed Assets (USD) | 24.15M | 30.51M | 36.43M | 41.58M | 32.50M | 24.90M | 30.07M | 34.07M | 37.92M | 14.56M | 8.55M | 6.60M | 9.24M | 14.33M | 18.40M |
| Noncurrent Assets (USD) | 409.03M | 764.77M | 1.00B | 915.01M | 905.84M | 58.39M | 66.94M | 38.62M | 42.47M | 28.87M | 20.57M | 6.76M | 9.73M | 14.68M | 18.72M |
| Other Current Assets (USD) | 325.77M | 436.93M | 685.37M | 801.69M | 1.08B | 341.36M | 67.73M | 113.78M | 14.34M | 91.04M | 98.26M | 106.43M | 116.41M | 105.41M | 184.08M |
| Prepaid Expenses (USD) | - | - | - | - | - | - | - | - | 1.32M | 2.34M | 1.33M | - | - | - | - |
| Inventory (USD) | 49.29M | 58.76M | 56.68M | 50.38M | 24.60M | 14.23M | 13.31M | 17.88M | 23.07M | 15.63M | 10.96M | 11.34M | 10.05M | 9.59M | 15.52M |
| Cash (USD) | - | - | - | - | - | - | - | - | 62.90M | - | - | - | - | - | - |
| Current Assets (USD) | 375.05M | 495.68M | 742.05M | 852.07M | 1.10B | 355.59M | 81.05M | 131.66M | 101.62M | 109.01M | 110.54M | 117.76M | 126.46M | 115.00M | 199.60M |
| Assets (USD) | 784.08M | 1.26B | 1.75B | 1.77B | 2.01B | 413.98M | 147.99M | 170.28M | 144.08M | 137.88M | 131.11M | 124.52M | 136.19M | 129.68M | 218.32M |
News and Insights
PacBio will participate in two upcoming investor conferences: Canaccord Genuity 45th Annual Growth Conference in Boston and Morgan Stanley 23rd Annual Global Healthcare Conference in New York, with live webcasts available.
The long-read sequencing market is projected to grow significantly, driven by the increasing adoption of next-generation sequencing technologies in genomic research, precision medicine, and genetic disease diagnostics. The U.S. market is expected to surge, benefiting from federal funding and a well-established infrastructure supporting these applications.
The global metagenomics market is projected to reach $6.71 billion by 2031, growing at a CAGR of 15.6% from 2024 to 2031. Key drivers include declining sequencing costs, increasing agricultural genomics focus, and genome mapping initiatives. Challenges include high instrument costs and a shortage of skilled professionals.
PacBio announced the conclusion of an independent investigation into employment and cybersecurity allegations, reporting its Q1 2025 financial results, and the launch of a newborn screening initiative in Thailand using its HiFi whole genome sequencing technology.
PacBio, a leading provider of DNA sequencing platforms, announced that it has granted a non-qualified stock option and restricted stock units to a recently hired employee as an inducement to join the company.
The global RNA transcriptome profiling test market is expected to grow at a CAGR of 14.5% and reach a valuation of US$ 37,383.8 million by 2034, driven by increasing investments in biotechnology and genomics for the detection of chronic diseases.
Ark Invest has been adding to its positions in Amazon, GitLab, and Pacific Biosciences of California. Amazon's stock hit an all-time high last month, and analysts see further upside. GitLab's recent financial results exceeded expectations, while Pacific Biosciences has struggled but Ark remains a believer in its long-term potential.
Shrimp Hydrolysate Market Set to Surge to $675.9 Million with an Impressive 8.7% CAGR by 2034positive
The global shrimp hydrolysate market is projected to grow at 7% CAGR and reach US$ 675.9 million by 2034, driven by the growing need for sustainable and nutrient-rich animal feed, aquaculture commodities, and food ingredients.
Cathie Wood's Ark Invest added to positions in The Trade Desk, Pacific Biosciences, and Guardant Health. The Trade Desk had a strong quarter, while PacBio's results were less impressive. Guardant Health's results were well-received by the market.